Back to School: How biopharma can reboot drug development. Access exclusive analysis here

Angiomax: Tortured path to a lot of competition

It has been a long road for Angiomax bivalirudin, a direct thrombin inhibitor derived from the leech compound hirudin. Biogen Inc. stopped development of the compound, then called Hirulog, in 1994 after a Phase III trial in angioplasty failed to show the compound's superiority to heparin. In March 1997, BGEN sold the compound

Read the full 539 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury


Article Purchase

This article may not be distributed to non-subscribers